

1 **Immediate post-operative PDE5i Therapy improves early Erectile Function Outcomes after**  
2 **Robot Assisted Radical Prostatectomy (RARP)**

3

4 **Authors:**

5 A. Nathan<sup>1,2,\*</sup>, S. Shukla<sup>2,\*</sup>, A. Sinha<sup>2</sup>, S. Sivathasan<sup>1</sup>, A. Rashid<sup>2</sup>, J. Rassam<sup>1</sup>, S. Smart<sup>1</sup>, K.  
6 Patel<sup>1</sup>, N. Shah<sup>1</sup>, B.W. Lamb<sup>1</sup>

7

8 arjun.nathan1@nhs.net [Corresponding Author]

9 ss2551@cam.ac.uk

10 as2559@cam.ac.uk

11 sailantra.sivathasan@addenbrookes.nhs.uk

12 ar793@cam.ac.uk

13 joseph.rassam@addenbrookes.nhs.uk

14 sonny.smart@addenbrookes.nhs.uk

15 keval.patel@addenbrookes.nhs.uk

16 nimish.shah@addenbrookes.nhs.uk

17 benjamin.lamb@addenbrookes.nhs.uk

18

19 <sup>1</sup>Addenbrooke's Hospital, Cambridge

20 <sup>2</sup>University of Cambridge

21 \* Both authors contributed equally to the manuscript

22

23 **Word Count: 2486 (max 4000)**

24 **Word Count (Abstract): 396**

25 **Tables: 4**

26 **Figures: 3**

27 **References: 43**

28

29 **Keywords:** Potency, Erectile Dysfunction, Phosphodiesterase Inhibitors (PDE5i), Robot-  
30 Assisted Radical Prostatectomy (RARP), Continence

31 **Abstract**

32

33 **Objectives**

34 To assess whether the timing of post-operative Phosphodiesterase Inhibitor (PDE5i) therapy  
35 after Robot Assisted Radical Prostatectomy (RARP) is associated with a change in early  
36 erectile function outcomes. Additionally, to determine whether there are differences in  
37 continence or safety outcomes.

38

39 **Subjects/patients and methods**

40 Data was prospectively collected from a single surgeon in one tertiary centre and  
41 retrospectively evaluated. 158 patients were treated with PDE5i therapy post RARP over a  
42 two-year period. PDE5i therapy was started: immediately (day 1-2) post-op in 29%, early  
43 (day 3-14) post-op in 37% and late (after day 14) post-op in 34%. EPIC-26 Erectile Function  
44 (EF) scores were collected pre-op and post-op with a median follow-up time of 43 days.

45

46 **Results**

47 The median age was 64 and the median BMI was 27. 9% of the series had Charlson Co-  
48 Morbidities. There were no significant differences in pre-operative characteristics between  
49 the therapy groups.

50 Patients that had bilateral nerve sparing had a mean drop in Erectile Function (EF) score by  
51 5.4 compared to 8.8 in the unilateral group. Additionally, 34.9% of bilateral nerve sparing  
52 patients returned to baseline compared to 12.1% of unilateral.

53 Drop in EF scores and percentage return to baseline for unilateral nerve sparing was  
54 respectively 9 and 11.1% of immediate therapy, 7 and 14.8% of early therapy and 9.7 and  
55 9.5% of late therapy ( $p=0.9$  and  $p=0.6$ ). For bilateral nerve sparing this was respectively 3.5  
56 and 42.9% immediate therapy, 5.5 and 35.5% early therapy and 7.3 and 25% late therapy  
57 ( $p=0.017$  and  $p=0.045$ ).

58 Pad free and social continence was achieved in 54% and 37% of those receiving immediate  
59 therapy, 60% and 33% for early therapy and 26% and 54% for late therapy. There were no  
60 differences in compliance, complication or readmission outcomes.

61

62 **Conclusion**

63 In patients with bilateral nerve sparing RARP, immediate post-operative PDE5i therapy may  
64 protect EF. Early onset (3-14 days) may also provide a benefit compared to initiating PDE5i  
65 therapy later (after 14 days). Expediting therapy for patients undergoing unilateral nerve  
66 sparing may also provide a benefit; however, the differences are less pronounced.  
67 Immediate or early PDE5i therapy also improved early continence outcomes for patients  
68 with bilateral nerve sparing, compared to late therapy. There were no differences in  
69 compliance, complication or readmission rates between the groups. Therefore, immediate  
70 PDE5i therapy should be considered in patients following nerve sparing RARP in order to  
71 maximise functional outcomes, especially in those undergoing bilateral nerve spare.

## 72 **Introduction**

73

74 Prostate Cancer (PCa) is the most commonly diagnosed cancer in men within the UK,  
75 accounting for 26% of all oncological diagnoses in 2017 (1). The 2019 National Prostate  
76 Cancer Audit (NPCA) reported that 33% of 21,896 men treated for PCa underwent radical  
77 prostatectomy (2). Robot Assisted Radical Prostatectomy (RARP) is a minimally invasive  
78 procedure which has been rapidly adopted by urological surgeons worldwide (3). Despite  
79 the learning curve and costs involved, RARP has shown equal or better cancer and quality  
80 outcomes compared to open surgery (4-6).

81

82 Despite the benefits of RARP, post-operative Erectile Dysfunction (ED) continues to be an  
83 issue for patients. A meta-analysis of potency rates by Ficcaro *et al* (7) reported the  
84 incidence of ED in men undergoing either unilateral or bilateral nerve sparing to be 68%,  
85 47%, 31% and 37% at 3, 6, 12 and 24 month follow-up intervals. When considering bilateral  
86 nerve-sparing only the ED rates were better at 44%, 31%, 26%, and 18% respectively. Return  
87 to baseline function takes approximately six months to two years (8). Furthermore, early  
88 potency rates post RARP can be as low as 33% during the six-month follow-up period (9).  
89 Salvage RARP has shown inferior Erectile Function (EF) outcomes compared to primary RARP  
90 with only 5% maintaining their pre-operative EF with two-year follow-up (10).

91

92 Crucially, EF has been shown to have significant effects on the psychological wellbeing of  
93 patients with studies showing over half of patients (51.6%) can feel angry, bitter or  
94 depressed at the loss of potency (11, 12).

95

96 As well as being affected by age, BMI, co-morbidities, baseline erectile function and nerve-  
97 sparing, EF outcomes are also affected by the use of penile rehabilitation therapy following  
98 surgery (13).

99

100 The use of phosphodiesterase inhibitors (PDE5i) following RARP, as part of penile  
101 rehabilitation, has been shown to preserve EF. ED post RARP can be explained by intra-  
102 operative damage to the pelvic splanchnic nerves. Upon sexual stimulation the pelvic  
103 splanchnic nerves release Nitric Oxide (NO) from Non-Noradrenergic Non-Cholinergic  
104 (NANC) fibres and Acetylcholine (ACh) from parasympathetic fibres leading to an overall  
105 increase in cyclic-GMP (cGMP) concentration. Subsequently there is a reduction in calcium  
106 ion concentration leading to the relaxation of vascular smooth muscle. Laboratory studies  
107 have demonstrated that PDE5i's block the action of phosphodiesterase which acts to break  
108 down cGMP, thereby working to reduce calcium ion concentration and promoting relaxation  
109 of vascular smooth muscle (14, 15).

110

111 Furthermore, numerous clinical studies have shown that the use of PDE5i's following RARP  
112 improve EF for patients with nerve-sparing surgery. Briganti *et al* followed patients treated  
113 by high volume surgeons with bilateral nerve sparing over a period of three-years. They  
114 found EF recovery rates to be significantly higher (73%) in the PDE5i therapy group  
115 compared to the placebo (37%) group (16). Similarly, Nelson *et al* found the EF recovery rate  
116 in the PDE5i group to be 43% compared to the placebo group of 22% at two-years post-op  
117 (17). Mulhall *et al* found that three months of on-demand 200mg Avanafil treatment  
118 significantly improved EF, with outcomes of 41% in the treatment group and 10.7% in the

119 placebo group (18). Current favourable evidence is better established for bilateral nerve  
120 sparing compared to unilateral nerve sparing (19, 20). The limited evidence for PDE5i  
121 therapy for patients with no nerve sparing shows no benefit (21).

122

123 Despite considerable evidence supporting the efficacy of PDE5i therapy on EF post RARP,  
124 there are few guidelines or evidence-based recommendations advising the optimal time to  
125 begin PDE5i therapy to begin post RARP. Teloken *et al* questioned 301 doctors from 41  
126 countries and found 95% use PDE5i therapy post RARP however only 6% initiate therapy  
127 immediately post-operatively. 54% waited until after the catheter removal around two  
128 weeks and the remaining 40% all started therapy at some point in the first four months (22).  
129 Moreover, some studies have suggested that the early use of PDE5i may be associated with  
130 an increased incidence of adverse events and worsen early continence outcomes (23, 24).

131

### 132 **Aims**

133

134 We aim to assess if there is an association between the timing of initiation of PDE5i therapy  
135 and early EF outcomes. Additionally, we aim to assess if the timing of initiation of PDE5i  
136 therapy is associated with adverse events or if it affects continence outcomes.

137 **Subjects/Patients and Methods**

138

139 Data was prospectively collected from a single surgeon at one tertiary centre. Data was then  
140 retrospectively evaluated. All patients were registered as part of The BAUS national  
141 outcomes audit and registered with the institutional audit department (Ref. PRN8750). 187  
142 patients who underwent primary RARP were identified over a two-year period from 2018 to  
143 2020, from these 158 patients were treated with PDE5i therapy. 29 patients did not receive  
144 PDE5i therapy due to non-nerve sparing status or lack of patient interest and were  
145 excluded.

146

147 The decision to attempt nerve sparing surgery was made jointly between the operating  
148 surgeon and patient based on a synthesis of patient priorities and disease factors.  
149 Specifically, patient priorities included the relative prioritisation of functional recovery and  
150 oncological control. Disease factors included the location lesion on the MRI scan, PSA level,  
151 as well as the distribution and grade of biopsy cores with PCa. Finally, digital rectal  
152 examination under anaesthesia was performed at the start of the case. The definition of  
153 nerve sparing included intrafascial and interfascial, as well as high- and low-release of the  
154 neurovascular bundle. The execution of nerve sparing reflected the intent as set out above,  
155 as well as what was intraoperatively feasible. All patients gave informed consent for surgery  
156 and PDE5i therapy. All patients were included in the analysis regardless of baseline EF or  
157 nerve-sparing status.

158

159 Three cohorts were stratified based on the time PDE5i therapy was initiated post RARP.  
160 Tadalafil 5mg once daily was the PDE5i of choice. In 2018, patients were started on late  
161 therapy however due to emerging evidence, practice was changed to starting therapy  
162 immediately post-op (25-27). Furthermore, due to anecdotal concerns regarding safety,  
163 initiation time was delayed to early post-operative therapy (28). Some patients received  
164 specific treatment depending on individual risk factors such as nerve-sparing status and risk  
165 of haematoma.

166

167 EF and post-operative continence were measured using the patient reported outcome  
168 measure (PROM) - The Expanded Prostate Cancer Index Composite Short Form (EPIC-26).  
169 EPIC -26 is a questionnaire designed to measure Quality of Life issues in patients with PCa.  
170 EF was measured using questions 8-11 with a minimum score of 5/24 and a maximum score  
171 of 24/24 (29).

172

173 Pre-operative metrics such as age, BMI, Charlson Co-Morbidities and intra-operative nerve  
174 spare status; as well as post-operative data on continence, complications, readmission and  
175 discontinuation were also collected.

176

177 Return to Baseline was defined as the post-operative EF score equalling or exceeding the  
178 pre-operative EF score (30). Full continence was defined as using zero pads per day, social  
179 continence was defined as using one pad per day and incontinence was defined as using  
180 two or more pads per day (31, 32).

181

182 Data collection, tables and figures were completed using Microsoft Excel 2019. Statistical  
183 analysis was done using SPSS 26<sup>th</sup> Edition, IBM. Chi-Squared tests were used to compare

184 categorical data and independent T-tests and ANOVA were used to compare continuous  
185 data.

186 **Results**

187

188 **Demographics**

189 For the entire cohort, median age was 64 (IQR: 59-67); median BMI was 27 (25-30); Charlson  
190 Co-Morbidities were present in 9%. Forty-six (29%) patients received PDE5i therapy  
191 immediately between day 1-2 (median = day 1) post-operatively. 58 (37%) patients received  
192 PDE5i therapy early between day 3-14 (median = day 10) post-operatively. 54 (34%) patients  
193 received PDE5i therapy late after day 14 (median = day 40). There were no statistically  
194 significant differences in age, BMI, Co-Morbidities or pre-operative EF scores between the  
195 three groups. 53% of our cohort had bilateral nerve-sparing, 42% had unilateral nerve-  
196 sparing and 6% had no nerve-sparing (Table 1). The median follow-up time was 43 days  
197 (IQR: 41-47).

198

199 **Erectile Function Outcomes**

200 There was a mean drop in EF score of 9.4 and return to baseline of 22% for no nerve  
201 sparing. Unilateral nerve sparing achieved 8.8 and 12% whilst bilateral achieved 5.4 and  
202 35% ( $p<0.05$ ) (Table 2).

203

204 The mean pre-operative EF score was 17.4 out of 24, mean drop in EF score was 7 and the  
205 return to baseline was 25%. Mean drop in EF and return to baseline was 5.7 and 36% with  
206 immediate therapy, 6.6 and 39% with early therapy and 8.6 and 26% with late therapy  
207 ( $p=0.097$  and  $p=0.374$ ) (Table 3).

208

209 For unilateral nerve spare, mean drop in EF score and return to baseline was 9 and 11% for  
210 immediate, 7 and 15% for early and 9.7 and 10% for late. For bilateral nerve spare, mean  
211 drop in EF score and return to baseline was 3.5 and 43% for immediate, 5.5 and 36% for  
212 early and 7.3 and 25% for late ( $p<0.05$ ) (Table 4) (Fig 1) (Fig 2).

213

214 **Continence Outcomes**

215 Overall, in our entire cohort, full continence was achieved by 47%, social continence 41%,  
216 with 12% remaining incontinent, at a follow-up of 6-8 weeks. Between therapy groups, rates  
217 of full and social continence were 54% and 37% in immediate therapy, 60% and 33% in early  
218 therapy and 26% and 54% in late therapy ( $p<0.05$ ) (Table 3) (Fig 3).

219

220 **Safety Outcomes**

221 PDE5i therapy, in the total cohort, was stopped in 13%, with 7% stopping due to side effects  
222 and 6% due to non-compliance. From the entire cohort 2% were readmitted and 5%  
223 developed 90-day complications of which one was a haematoma, managed conservatively.  
224 There were no statistically significant differences between the three groups for  
225 discontinuation, complications or readmission (Table. 3).

226

## 227 **Discussion**

228

229 Our results suggest that patients who were started earlier on PDE5i therapy after RARP  
230 enjoyed better EF outcomes overall. Specifically, the mean drop in EF score showed a trend  
231 towards being reduced in the immediate (5.7) and early (6.6) therapy groups compared to  
232 late therapy (8.6) group for all nerve sparing groups, though this did not reach statistical  
233 significance ( $p=0.097$ ). Furthermore, return to baseline EF score trended towards  
234 improvement in the immediate (36%) and early (39%) groups compared to 26% in late  
235 group, though this was not statistically significant ( $p=0.374$ ).

236

237 However, when utilising nerve sparing techniques, immediate therapy showed significant  
238 benefit compared to late therapy. These results were more pronounced in bilateral nerve  
239 sparing. For bilateral nerve sparing, immediate therapy had a higher EF score by 3.8  
240 compared to late therapy ( $p=0.04$ ). Additionally, return to baseline in immediate therapy  
241 was 17.9% higher compared to late therapy ( $p=0.05$ ) and early therapy was 10.5% higher  
242 than late therapy ( $p=0.05$ ). Immediate and early PDE5i therapy in unilateral nerve sparing  
243 also showed greater EF outcomes compared to late therapy, however the differences were  
244 not statistically significant.

245

246 Continence outcomes were also better in immediate or early therapy compared to late  
247 therapy for all patients. Full continence and social continence were achieved by 54% and  
248 37% in the immediate group, 60% and 33% in the early group and only 26% and 54% in the  
249 late group ( $p=0.001$ ). Additionally, there were no differences in compliance, complications  
250 or readmissions between the three therapy groups.

251

252 A novel finding from our data showed 11% ( $n=18$ ) of our cohort recovered EF above  
253 baseline. This is possibly due to untreated pre-existing erectile dysfunction. In this cohort  
254 median pre-operative EF was 11 with a median increase of 4.

255

256 Our results show that the level of preservation of the neurovascular bundle is important in  
257 erectile function recovery post RARP, as previously described (7, 33). For example, Greco *et al*  
258 (34) showed 69% return to sexual intercourse with bilateral nerve sparing compared to  
259 43% in unilateral. Additionally, Sridhar *et al* (21) found that for patients with non-nerve  
260 sparing surgery, post-operative treatment with PDE5i made no significant difference to EF.

261

262 PDE5i therapy is a well-established component of penile rehabilitation after RARP. Montorsi  
263 *et al* (25) showed significantly greater EF scores using on-demand Sildenafil compared to  
264 placebo. Pace *et al* (26) also showed improved potency rates using Sildenafil (87%)  
265 compared to placebo (56%). Generally, starting PDE5i therapy earlier post-operatively  
266 showed better EF score results (35). However, our study adds further weight to the previous  
267 limited evidence that earlier post-operative PDE5i therapy improves EF. We showed a mean  
268 drop in EF and return to baseline was 5.7 and 36% in the immediate group, 6.6 and 39% in  
269 the early group and 8.6 and 26% in the late group. Comparison of different PDE5i has shown  
270 71% of patients preferred Tadalafil and 29% preferred Sildenafil due to side-effect and  
271 erection profile (36).

272

273 Studies have shown that PDE5i therapy after RARP may also improve urinary continence  
274 outcomes (19, 37, 38). Kaiho *et al* (24) showed that immediate PDE5i therapy may  
275 temporarily worsen immediate incontinence compared to late therapy. However, our data  
276 showed an improvement in early continence rates with immediate PDE5i therapy compared  
277 to late therapy. Furthermore, considering anecdotal and pharmacological concerns  
278 regarding increased bleeding, our study did not show any differences in adverse effects  
279 when initiating PDE5i therapy immediately after RARP (28).

280

281 Numerous studies have documented the poor quality of life associated with ED, with most  
282 suffering from moderate to severe psychological effects. Common concerns reported  
283 included partnership issues, guilt, anger and self-deprecation (39, 40).

284

285 Rates of ED after RARP have been reported to be as high as 68% and non-surgical  
286 interventions such as focal therapy and radiotherapy report lower rates of ED (7, 41-43).  
287 Therefore, immediate PDE5i therapy after RARP should be considered in order to achieve  
288 the best possible EF outcome for patients and improve overall satisfaction after RARP.

289

290 Despite multiple studies proving the benefit of PDE5i therapy after RARP, there is no clear  
291 consensus or pathway implemented for the management of ED after RARP. In general,  
292 PDE5i therapy is started four to six weeks post-operatively however our results show that  
293 immediate or early PDE5i therapy can improve EF outcomes with no adverse effects. We  
294 recommend the use of immediate PDE5i therapy for patients undergoing nerve sparing  
295 RARP to improve EF outcomes, continence outcomes and patient satisfaction.

296

297 Limitations of this study include single-surgeon data with an associated surgical learning  
298 curve confounder which may mask smaller effects in the results. The study also lacks  
299 randomisation and multiple follow-up intervals to assess longer term trends.

300

301 Further research with randomisation of patients in multiple centres with longer follow-up  
302 would improve the quality of the results. Pre-operative PDE5i therapy may also show a  
303 benefit to EF outcomes. Additionally, a cost-benefit analysis of extended PDE5i use with  
304 respect to quality of life should be undertaken.

305

306 **Conclusion**

307

308 In conclusion, immediate or early post-operative PDE5i therapy after RARP trends towards  
309 better early EF outcomes compared to late therapy. This effect is significantly more  
310 pronounced in patients undergoing bilateral nerve sparing. There may also be a benefit in EF  
311 for patients with unilateral nerve sparing, however the effects are less pronounced.  
312 Immediate therapy can also improve early continence outcomes and does not show an  
313 increase in adverse outcomes. Preservation of sexual function and regaining continence are  
314 important factors for patients undergoing RARP and therefore immediate therapy should be  
315 considered especially in bilateral nerve sparing cases.

316

317 **Acknowledgments**

318

319 Urology Department Addenbrooke's Hospital, Cambridge University Hospitals

320

321 **Conflict of Interest**

322

323 All authors confirm they have no conflict of interest

324 References

325

- 326 1. UK CR. Prostate Cancer Incidence Statistics 2019 [Available from:  
327 [https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Zero)  
328 [cancer-type/prostate-cancer/incidence#heading-Zero](https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Zero).
- 329 2. Audit NPC. NPCA Annual Report 2019. 2020.
- 330 3. Orvieto MA, Patel VR. Evolution of robot-assisted radical prostatectomy. *Scand J*  
331 *Surg.* 2009;98(2):76-88.
- 332 4. Abboudi H, Khan MS, Guru KA, Froghi S, de Win G, Van Poppel H, et al. Learning  
333 curves for urological procedures: a systematic review. *BJU Int.* 2014;114(4):617-29.
- 334 5. Krambeck AE, DiMarco DS, Rangel LJ, Bergstralh EJ, Myers RP, Blute ML, et al. Radical  
335 prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic  
336 and robot-assisted techniques. *BJU Int.* 2009;103(4):448-53.
- 337 6. Trinh QD, Sammon J, Sun M, Ravi P, Ghani KR, Bianchi M, et al. Perioperative  
338 Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical  
339 Prostatectomy: Results From the Nationwide Inpatient Sample. *European Urology.*  
340 2012;61(4):679-85.
- 341 7. Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, et al. Systematic  
342 Review and Meta-analysis of Studies Reporting Potency Rates After Robot-assisted Radical  
343 Prostatectomy. *European Urology.* 2012;62(3):418-30.
- 344 8. Tewari A, Srivasatava A, Menon M. A prospective comparison of radical retropubic  
345 and robot-assisted prostatectomy: experience in one institution. *BJU Int.* 2003;92(3):205-10.
- 346 9. Kim SC, Song C, Kim W, Kang T, Park J, Jeong IG, et al. Factors Determining Functional  
347 Outcomes After Radical Prostatectomy: Robot-Assisted Versus Retropubic. *European*  
348 *Urology.* 2011;60(3):413-9.
- 349 10. De Groote R, Nathan A, De Bleser E, Pavan N, Sridhar A, Kelly J, et al. Techniques and  
350 Outcomes of Salvage Robot-Assisted Radical Prostatectomy (sRARP). *Eur Urol.* 2020.
- 351 11. Huri HZ, Mat Sanusi ND, Razack AH, Mark R. Association of psychological factors,  
352 patients' knowledge, and management among patients with erectile dysfunction. *Patient*  
353 *Prefer Adherence.* 2016;10:807-23.
- 354 12. Latini DM, Penson DF, Colwell HH, Lubeck DP, Mehta SS, Henning JM, et al.  
355 Psychological impact of erectile dysfunction: validation of a new health related quality of life  
356 measure for patients with erectile dysfunction. *J Urol.* 2002;168(5):2086-91.
- 357 13. Montorsi F, Wilson TG, Rosen RC, Ahlering TE, Artibani W, Carroll PR, et al. Best  
358 Practices in Robot-assisted Radical Prostatectomy: Recommendations of the Pasadena  
359 Consensus Panel. *European Urology.* 2012;62(3):368-81.
- 360 14. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. *Int J*  
361 *Impot Res.* 2004;16(1):S4-S7.
- 362 15. John Hubert WP. *Robotic Urology.* 3 ed: Springer International Publishing; 2018.
- 363 16. Briganti A, Gallina A, Suardi N, Capitanio U, Tutolo M, Bianchi M, et al. Predicting  
364 erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of  
365 a novel preoperative risk stratification. *J Sex Med.* 2010;7(7):2521-31.
- 366 17. Nelson CJ, Scardino PT, Eastham JA, Mulhall JP. Back to baseline: erectile function  
367 recovery after radical prostatectomy from the patients' perspective. *J Sex Med.*  
368 2013;10(6):1636-43.
- 369 18. Mulhall JP, Burnett AL, Wang R, McVary KT, Moul JW, Bowden CH, et al. A Phase 3,  
370 Placebo Controlled Study of the Safety and Efficacy of Avanafil for the Treatment of Erectile

- 371 Dysfunction After Nerve Sparing Radical Prostatectomy. *Journal of Urology*.  
372 2013;189(6):2229-36.
- 373 19. Patel HR, Ilo D, Shah N, Cuzin B, Chadwick D, Andrianne R, et al. Effects of tadalafil  
374 treatment after bilateral nerve-sparing radical prostatectomy: quality of life, psychosocial  
375 outcomes, and treatment satisfaction results from a randomized, placebo-controlled phase  
376 IV study. *BMC Urol*. 2015;15:31.
- 377 20. Brock G, Montorsi F, Costa P, Shah N, Martinez-Jabaloyas JM, Hammerer P, et al.  
378 Effect of Tadalafil Once Daily on Penile Length Loss and Morning Erections in Patients After  
379 Bilateral Nerve-sparing Radical Prostatectomy: Results From a Randomized Controlled Trial.  
380 *Urology*. 2015;85(5):1090-6.
- 381 21. Sridhar AN, Cathcart PJ, Yap T, Hines J, Nathan S, Briggs TP, et al. Recovery of  
382 Baseline Erectile Function in Men Following Radical Prostatectomy for High-Risk Prostate  
383 Cancer: A Prospective Analysis Using Validated Measures. *J Sex Med*. 2016;13(3):435-43.
- 384 22. Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy  
385 pharmacological penile rehabilitation: practice patterns among the international society for  
386 sexual medicine practitioners. *J Sex Med*. 2009;6(7):2032-8.
- 387 23. Berkels R, Klotz T, Sticht G, Englemann U, Klaus W. Modulation of human platelet  
388 aggregation by the phosphodiesterase type 5 inhibitor sildenafil. *J Cardiovasc Pharmacol*.  
389 2001;37(4):413-21.
- 390 24. Kaiho Y, Yamashita S, Ito A, Kawasaki Y, Izumi H, Kawamorita N, et al.  
391 Phosphodiesterase type 5 inhibitor administered immediately after radical prostatectomy  
392 temporarily increases the need for incontinence pads, but improves final continence status.  
393 *Investig Clin Urol*. 2016;57(5):357-63.
- 394 25. Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, et al. Effect of nightly  
395 versus on-demand vardenafil on recovery of erectile function in men following bilateral  
396 nerve-sparing radical prostatectomy. *Eur Urol*. 2008;54(4):924-31.
- 397 26. Pace G, Del Rosso A, Vicentini C. Penile rehabilitation therapy following radical  
398 prostatectomy. *Disabil Rehabil*. 2010;32(14):1204-8.
- 399 27. Jo JK, Jeong SJ, Oh JJ, Lee SW, Lee S, Hong SK, et al. Effect of Starting Penile  
400 Rehabilitation with Sildenafil Immediately after Robot-Assisted Laparoscopic Radical  
401 Prostatectomy on Erectile Function Recovery: A Prospective Randomized Trial. *J Urol*.  
402 2018;199(6):1600-6.
- 403 28. Schwartz BG, Kloner RA. Drug interactions with phosphodiesterase-5 inhibitors used  
404 for the treatment of erectile dysfunction or pulmonary hypertension. *Circulation*.  
405 2010;122(1):88-95.
- 406 29. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of  
407 the expanded prostate cancer index composite (EPIC) for comprehensive assessment of  
408 health-related quality of life in men with prostate cancer. *Urology*. 2000;56(6):899-905.
- 409 30. Tewari AK, Srivastava A, Huang MW, Robinson BD, Shevchuk MM, Durand M, et al.  
410 Anatomical grades of nerve sparing: a risk-stratified approach to neural-hammock sparing  
411 during robot-assisted radical prostatectomy (RARP). *BJU Int*. 2011;108(6B):984-92.
- 412 31. Sridhar AN, Abozaid M, Rajan P, Sooriakumaran P, Shaw G, Nathan S, et al. Surgical  
413 Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical  
414 Prostatectomy for Prostate Cancer. *Curr Urol Rep*. 2017;18(9):71.
- 415 32. Nathan A, Mazzon G, Pavan N, De Groote R, Sridhar A, Nathan S. Management of  
416 intractable bladder neck strictures following radical prostatectomy using the  
417 Memokath(®)045 stent. *J Robot Surg*. 2019.

- 418 33. Ficarra V, Borghesi M, Suardi N, De Naeyer G, Novara G, Schattelman P, et al. Long-  
419 term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted  
420 radical prostatectomy (RARP). *BJU Int.* 2013;112(3):338-45.
- 421 34. Greco F, Hoda MR, Wagner S, Reichelt O, Inferrera A, Magno C, et al. Bilateral vs  
422 unilateral laparoscopic intrafascial nerve-sparing radical prostatectomy: evaluation of  
423 surgical and functional outcomes in 457 patients. *BJU Int.* 2011;108(4):583-7.
- 424 35. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, et al.  
425 Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil  
426 citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical  
427 prostatectomy. *Int J Impot Res.* 2008;20(5):479-86.
- 428 36. Eardley I, Montorsi F, Jackson G, Mirone V, Chan MLS, Loughney K, et al. Factors  
429 associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction  
430 in men naive to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a  
431 multicentre, randomized, open-label, crossover study. *BJU Int.* 2007;100(1):122-9.
- 432 37. Hyndman ME, Bivalacqua TJ, Feng ZY, Mettee LZ, Su LM, Trock BJ, et al. Nightly  
433 sildenafil use after radical prostatectomy has adverse effects on urinary convalescence:  
434 Results from a randomized trial of nightly vs on-demand dosing regimens. *CUAJ-Can Urol*  
435 *Assoc J.* 2015;9(11-12):414-9.
- 436 38. Gacci M, Ierardi A, Delle Rose A, Tazzioli S, Scapaticci E, Filippi S, et al. Vardenafil can  
437 improve continence recovery after bilateral nerve sparing prostatectomy: Results of a  
438 randomized, double blind, placebo-controlled pilot study. *J Sex Med.* 2010;7(1):234-43.
- 439 39. Korfage IJ, Pluijm S, Roobol M, Dohle GR, Schroder FH, Essink-Bot ML. Erectile  
440 dysfunction and mental health in a general population of older men. *J Sex Med.*  
441 2009;6(2):505-12.
- 442 40. Tomlinson JM, Wright D. Impact of erectile dysfunction and its subsequent  
443 treatment with sildenafil: qualitative study. *BMJ-British Medical Journal.*  
444 2004;328(7447):1037-9.
- 445 41. Bahn DK, Silverman P, Lee F, Badalament R, Bahn ED, Rewcastle JC. Focal prostate  
446 cryoablation: Initial results show cancer control and potency preservation. *J Endourol.*  
447 2006;20(9):688-92.
- 448 42. Ellis DS, Manny TB, Rewcastle JC. Focal cryosurgery followed by penile rehabilitation  
449 as primary treatment for localized prostate cancer: Initial results. *Urology.* 2007;70(6A):9-  
450 15.
- 451 43. Cozzarini C, Rancati T, Palorini F, Avuzzi B, Garibaldi E, Balestrini D, et al. Patient-  
452 reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the dose-  
453 effect. *Radiother Oncol.* 2017;125(1):101-6.
- 454

## **Immediate post-operative PDE5i Therapy improves early Erectile Function Outcomes after Robot Assisted Radical Prostatectomy (RARP)**

### **Tables and Figures**

**Table. 1 Pre-operative and intraoperative characteristics of therapy groups by PDE5i therapy onset**

	Total	Immediate	Early	Late	P-Value
<b>Criteria (Day Post-Op)</b>		1-2	3-14	>14	
<b>N (%)</b>	158 (100)	46 (29)	58 (37)	54 (34)	
<b>Pre-Op Demographics</b>					
<b>Median Age (IQR) years</b>	64 (59-67)	66 (62-68)	62 (57-66)	64 (59-67)	0.916
<b>Median BMI (IQR)</b>	27 (25-30)	28 (25-30)	27 (25-30)	27 (24-29)	0.854
<b>Co-Morbidities N (%)</b>	14 (9)	3 (7)	4 (7)	7 (13)	0.424
<b>Nerve-Sparing Status</b>					
<b>Nil N (%)</b>	9 (6)	0 (0)	0 (0)	9 (6)	0.210
<b>Unilateral N (%)</b>	66 (42)	18 (11)	27 (17)	21 (13)	
<b>Bilateral N (%)</b>	83 (53)	28 (18)	31 (20)	24 (15)	

N = Numbers, \* = statistically significant at p<0.05

**Table. 2 Erectile Function Outcomes between nerve-sparing groups**

	Nil	Unilateral	Bilateral	P-Value
<b>N (%)</b>	9 (6)	66 (42)	83 (53)	
<b>Mean Drop EFs</b>	9.4	8.8	5.4	<b>0.005*</b>
<b>Return to Baseline (%)</b>	2 (22)	8 (12)	29 (35)	<b>0.005*</b>

N = Numbers, EFs = Erectile Function Score, \* = statistically significant at p<0.05

**Table. 3 Post-operative outcomes of therapy groups by PDE5i therapy onset**

	Total	Immediate	Early	Late	P-Value
<b>N (%)</b>	158 (100)	46 (29)	58 (37)	54 (34)	
<b>Erectile Function</b>					
<b>Mean Pre-Op EFs</b>	17.4	17.9	18.2	16.2	0.110
<b>Mean Drop EF</b>	7	5.7	6.6	8.6	0.097
<b>Return to Baseline N (%)</b>	39 (25)	14 (36)	15 (39)	10 (26)	0.374
<b>Continence</b>					
<b>Full Continence N (%)</b>	74 (47)	25 (54)	35 (60)	14 (26)	<b>0.001*</b>
<b>Social Continence N (%)</b>	65 (41)	17 (37)	19 (33)	29 (54)	<b>0.043*</b>
<b>Incontinence N (%)</b>	19 (12)	4 (9)	4 (7)	11 (20)	0.065
<b>Safety</b>					
<b>Stopped N (%)</b>	21 (13)	6 (13)	3 (5)	12 (22)	0.589
<b>-Due to Side Effects N (%)</b>	11 (7)	5 (11)	2 (3)	4 (7)	0.934
<b>-Due to Compliance (%)</b>	10 (6)	1 (2)	1 (2)	8 (15)	0.574
<b>Complications N (%)</b>	8 (5)	2 (4)	2 (3)	4 (7)	0.948
<b>Readmissions N (%)</b>	3 (2)	1 (2)	1 (2)	1 (2)	0.865

N = Numbers, EFs = Erectile Function Score, \* = statistically significant at p<0.05

Full continence = 0 pads, Social continence = 1 pad / day, Incontinence = 2 or more pads / day


**Table.4 Erectile Function outcomes by nerve spare and PDE5i therapy onset**

	Total	Immediate			Early			Late		
Nerve-sparing		Nil	Uni	Bi	Nil	Uni	Bi	Nil	Uni	Bi
<b>N</b>	158	0	18	28	0	27	31	9	21	24
<b>Mean Pre-Op EFs</b>	17.4	-	18.2	17.7	-	17	19.2	14.7	16.1	16.9
<b>Mean Drop EFs</b>	7	-	9	3.5	-	7	5.5	9.4	9.7	7.3
<b>Return to Baseline (%)</b>	39 (24.7)	-	2 (11.1)	12 (42.9)	-	4 (14.8)	11 (35.5)	2 (22.2)	2 (9.5)	6 (25.0)
<b>Statistical Comparison</b>										
<b>Nerve-Sparing</b>		Unilateral (p-value)					Bilateral (p-value)			
<b>EF Score Change</b>										
<b>Immediate vs Late</b>		+0.6 (1.0)					<b>+3.8 (0.04)*</b>			
<b>Early vs Late</b>		+1.6 (0.9)					+1.8 (0.9)			
<b>Immediate vs Early</b>		+1 (0.9)					+1.9 (0.9)			
<b>Return to Baseline %</b>										
<b>Immediate vs Late</b>		+1.6 (0.6)					<b>+17.9 (0.05)*</b>			
<b>Early vs Late</b>		+5.3 (0.5)					<b>+10.5 (0.05)*</b>			
<b>Immediate vs Early</b>		-3.7 (0.8)					+7.4 (0.1)			

N = Numbers, \* = statistically significant at p<0.05


Uni = Unilateral, Bi = Bilateral, EFs = Erectile Function Score

**Figure. 1 EF Score compared between nerve spare and different PDE5i therapy onset groups. Showing significantly lower drops in EF score with immediate or early therapy in bilateral nerve spare groups.**




\* = statistically significant at  $p < 0.05$

**Figure. 2 Return to Baseline outcomes compared between nerve spare and different PDE5i therapy onset groups. Showing significantly improved return to baseline EF with immediate or early therapy in bilateral nerve spare groups.**



\* = statistically significant at  $p < 0.05$

**Figure. 3** Continence outcomes compared between different PDE5i therapy onset groups. Showing statistically significant improved return to full continence with immediate and early therapy.



\* = statistically significant at  $p < 0.05$